REAL LIFE COST OF TREATMENT AND FOLLOW-UP IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS TREATED AT THE ANTWERP UNIVERSITY HOSPITAL (UZA), BELGIUM
Author(s)
Van den Eede N1, De Paepe A1, Specenier P2, Strens D3
1University of Antwerp, Antwerpen, Belgium, 2Antwerp University Hospital, Edegem, Belgium, 3Realidad bvba, Grimbergen, Belgium
OBJECTIVES: To calculate the costs associated with the management of patients with GBM from diagnosis until death. METHODS: Charts of all patients with histologically confirmed GBM diagnosis between 2007 and 2016 at UZA were retrospectively reviewed. Eligible for this analysis were patients who deceased prior to August 2016, and for whom complete information on resource use is available at UZA. Resource use (hospitalization, tests, treatment, drugs) was collected per patient from GBM diagnosis till death. Costs were calculated using unit costs (2017) defined by the National Institute for Health and Disability Insurance (NIHDI). Average (bootstrap 95% confidence interval [CI]) costs per patient were calculated from both a public payer’s and patient’s perspective. RESULTS: at expense of the patient. Major cost driving factors are hospitalization (61%) and chemotherapy (17%) from a public payer’s perspective, and hospitalization (68%) and supportive medication (15%) from a patient’s perspective. The average cost for patients treated with surgery only is €33,736 (95% CI 25,356-42,913) of which €32,723 (95% CI 24,502-41,688) is covered by NIHDI. The average cost for patients treated with surgery and radiotherapy and/or chemotherapy is €50,389 (95% CI 39,731-62,193 ) of which €48,837 (95% CI 38,441-60,422 ) is covered by NIHDI. CONCLUSIONS: GBM is associated with considerable costs for both NIHDI and patient.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
CS4
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology